Payment overview · 2025
General Payments
$1,695.13
95 reported records · 14 companies
Healthcare provider profile · identity verified
Angela Dawn Lewis, DO
Allopathic & Osteopathic Physicians|Family Medicine · RUSSELL, KY · NPI 1710073580
Verified facts
What the public records show
CMS Open Payments records show Angela Dawn Lewis, DO received $1,695.13 in general payments during 2025 across 95 reported records.
PFIZER INC. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $328.48 | 19.4% | 27 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $253.31 | 14.9% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $208.03 | 12.3% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $196.87 | 11.6% | 12 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $177.54 | 10.5% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $141.77 | 8.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.77 | 8.4% | 10 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $64.46 | 3.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.12 | 3.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.33 | 2.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.29 | 1.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.01 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.30 | 1.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.85 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,650.13 | 94 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $253.31 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $238.76 | 22 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $177.54 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $151.87 | 11 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $151.87 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $144.63 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $141.77 | 10 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $141.77 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $124.19 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $120.78 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $106.16 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.95 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $64.46 | 4 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $51.65 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.71 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.29 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.33 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 163 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
119 | 36 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 576 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 552 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 457 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 450 | 117 |
| Omeprazole | Omeprazole | 413 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 382 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 363 | 102 |
| Lisinopril | Lisinopril | 342 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 339 | 104 |
| Metformin Hcl | Metformin Hcl | 326 | 87 |
| Gabapentin | Gabapentin | 304 | 63 |
| Losartan Potassium | Losartan Potassium | 303 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 282 | 74 |
| Montelukast Sodium | Montelukast Sodium | 268 | 71 |
| Potassium Chloride | Potassium Chloride | 245 | 76 |
| Sertraline Hcl | Sertraline Hcl | 243 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 231 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 212 | 41 |
| Furosemide | Furosemide | 208 | 62 |
| Simvastatin | Simvastatin | 191 | 51 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 170 | 43 |
| Tramadol Hcl | Tramadol Hcl | 169 | 30 |
| Eliquis | Apixaban | 163 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 159 | 43 |
| Clonazepam | Clonazepam | 143 | 29 |
| Lorazepam | Lorazepam | 141 | 29 |
| Pregabalin | Pregabalin | 136 | 33 |
| Alprazolam | Alprazolam | 131 | 20 |
| Carvedilol | Carvedilol | 126 | 34 |
| Synthroid | Levothyroxine Sodium | 119 | 36 |
| Allopurinol | Allopurinol | 117 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 34 |
| Meloxicam | Meloxicam | 115 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 111 | 37 |
| Famotidine | Famotidine | 110 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 104 | 34 |
| Cefdinir | Cefdinir | 103 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 98 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 24 |
| Farxiga | Dapagliflozin Propanediol | 89 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 85 | 27 |
| Ozempic | Semaglutide | 85 | 13 |
| Trazodone Hcl | Trazodone Hcl | 83 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 36 |
| Ezetimibe | Ezetimibe | 77 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 29 |
| Glimepiride | Glimepiride | 71 | 19 |
| Memantine Hcl | Memantine Hcl | 71 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 19 |
| Methocarbamol | Methocarbamol | 69 | 31 |
| Buspirone Hcl | Buspirone Hcl | 65 | 15 |
| Donepezil Hcl | Donepezil Hcl | 65 | 15 |
| Januvia | Sitagliptin Phosphate | 64 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 14 |
| Prednisone | Prednisone | 62 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 21 |
| Valsartan | Valsartan | 61 | 18 |
| Spironolactone | Spironolactone | 60 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 19 |
| Lansoprazole | Lansoprazole | 57 | 16 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 17 |
| Atenolol | Atenolol | 53 | 16 |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 49 | 13 |
| Celecoxib | Celecoxib | 48 | 16 |
| Diazepam | Diazepam | 48 | 17 |
| Bupropion Xl | Bupropion Hcl | 47 | 16 |
| Fenofibrate | Fenofibrate | 46 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Ramipril | Ramipril | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 11 |
| Estradiol | Estradiol | 43 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 41 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 13 |
| Klor-Con M20 | Potassium Chloride | 40 | 12 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 40 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 11 |
| Cephalexin | Cephalexin | 36 | 30 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 18 |
| Xarelto | Rivaroxaban | 34 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 11 |
| Pitavastatin Calcium | Pitavastatin Calcium | 32 | 11 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 20 |
| Valacyclovir | Valacyclovir Hcl | 25 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Nexium | Esomeprazole Magnesium | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Baclofen | Baclofen | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nystatin | Nystatin | 21 | 15 |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Livalo | Pitavastatin Calcium | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Metaxalone | Metaxalone | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Novolog Penfill | Insulin Aspart | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Wellbutrin Sr | Bupropion Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,695.13 · 95 records | PFIZER INC. | AREXVY, Auvelity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, VYNDAMAX, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error